Momentum Stock Watch: Sunesis Pharmaceuticals, Inc. (SNSS)

Company Profile:

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. The company was founded in 1998 and is headquartered in South San Francisco, California.

Recent News:

On Oct. 29, 2015, Sunesis Pharmaceuticals, Inc. will host a conference call on Thursday, November 5, 2015 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2015.

Sunesis Pharmaceuticals, Inc. announced two poster presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 5-9 in Boston, Massachusetts.

Sunesis Pharmaceuticals, Inc. intends to submit a Marketing Authorization Application (MAA) for vosaroxin as a treatment for acute myeloid leukemia (AML) with the European Medicines Agency (EMA) by the end of 2015.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



SNSS’s strengths can be seen in its better growth, strong Solvency, and robust efficiency. Technical indicators signal the bullish signs, as %K line is on top fo %D line and RSI is in bull territory, which stands at 44.53. The current P/BV ratio indicates it is undervalued compared to the average P/BV ratio of the industry and the sector. We rate Sunesis Pharmaceuticals, Inc. (SNSS) a Strong BUY.

About the Author

has written 15946 stories on this site.

Write a Comment

Gravatars are small images that can show your personality. You can get your gravatar for free today!

You must be logged in to post a comment.

Copyright © 2012 Nine Stocks